Payment overview · 2025
General Payments
$324.20
16 reported records · 12 companies
Healthcare provider profile · identity verified
James P Corcoran, DO
Allopathic & Osteopathic Physicians|Family Medicine · PHOENIX, AZ · NPI 1730128091
Verified facts
What the public records show
CMS Open Payments records show James P Corcoran, DO received $324.20 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.21 | 17.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.53 | 15.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.57 | 13.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.59 | 8.2% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.17 | 7.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.46 | 7.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $20.06 | 6.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.81 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.15 | 5.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.13 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.94 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.58 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $324.20 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.21 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.21 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 547 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 517 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 429 | 142 |
| Losartan Potassium | Losartan Potassium | 304 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 86 |
| Metformin Hcl | Metformin Hcl | 245 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 81 |
| Lisinopril | Lisinopril | 212 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 64 |
| Mounjaro | Tirzepatide | 161 | 29 |
| Trazodone Hcl | Trazodone Hcl | 155 | 45 |
| Pregabalin | Pregabalin | 152 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 151 | 46 |
| Omeprazole | Omeprazole | 129 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 43 |
| Allopurinol | Allopurinol | 111 | 36 |
| Ozempic | Semaglutide | 109 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 107 | 33 |
| Gabapentin | Gabapentin | 98 | 39 |
| Simvastatin | Simvastatin | 98 | 25 |
| Tramadol Hcl | Tramadol Hcl | 96 | 32 |
| Sertraline Hcl | Sertraline Hcl | 89 | 31 |
| Famotidine | Famotidine | 85 | 28 |
| Glimepiride | Glimepiride | 84 | 26 |
| Meloxicam | Meloxicam | 83 | 21 |
| Carvedilol | Carvedilol | 81 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 53 |
| Valsartan | Valsartan | 61 | 20 |
| Ezetimibe | Ezetimibe | 60 | 11 |
| Eliquis | Apixaban | 59 | 22 |
| Furosemide | Furosemide | 53 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 51 | 15 |
| Spironolactone | Spironolactone | 50 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Montelukast Sodium | Montelukast Sodium | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 49 | 15 |
| Atenolol | Atenolol | 48 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 15 |
| Azithromycin | Azithromycin | 46 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 17 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 15 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | 18 |
| Celecoxib | Celecoxib | 40 | 17 |
| Valacyclovir | Valacyclovir Hcl | 40 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Synthroid | Levothyroxine Sodium | 35 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 19 |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 30 |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | 12 |
| Glipizide | Glipizide | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Zaleplon | Zaleplon | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Prednisone | Prednisone | 20 | 12 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Prolia | Denosumab | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $324.20 · 16 records | PFIZER INC. | AIRSUPRA, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GEMTESA, JATENZO, NURTEC ODT, NUZYRA, Ozempic, PROCLAIM, PROLIA, Tlando, UBRELVY, Veozah, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error